If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-16. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Synthetic Fe–S clusters are laboratory-prepared coordination compounds or chains, often designed to mimic the structural, electronic, or chemical properties of biological Fe–S clusters. Roussin's black anion, [Fe4S3(NO)7]−, described in 1858, is the first synthetic Fe-S cluster. It has the geometry of an incomplete cubane-type cluster with C3v symmetry. The dark color of the complex is attributed to a number of charge-transfer interactions. Since the 1970s, many of these Fe-S clusters have been described. A key property of Fe–S clusters is their ability to undergo redox.
with equality in the equilateral case. More strongly, Barrow's inequality states that if the interior bisectors of the angles at interior point P (namely, of ∠APB, ∠BPC, and ∠CPA) intersect the triangle's sides at U, V, and W, then
restriction fragment length polymorphism (RFLP) Variability within a population of organisms observed in the size of the restriction fragments produced when genomic DNA (or any particular DNA molecule) is digested by one or more restriction endonucleases. This variability results from a corresponding polymorphism in the locations of restriction sites within the molecule(s) due to slight differences in nucleotide sequence between individuals. RFLP is frequently exploited in the laboratory to construct physical maps of the genome, to identify the specific locus occupied by a particular gene, and to detect genetic differences between closely related individuals or determine that different samples originated from the same individual. Analysis of restriction fragments can also reveal the presence of a mutation that may itself cause disease or be closely linked to one that does.
== Portraits == The National Portrait Gallery, London lists 17 portraits of Dorothy Hodgkin including an oil painting of her at her desk by Maggi Hambling and a photograph portrait by David Montgomery. Graham Sutherland made preliminary sketches for a portrait of Dorothy Crowfoot Hodgkin in 1978. One sketch is in the collection of the Science History Institute and another at the Royal Society in London. The portrait was never finished. A portrait of Dorothy Hodgkin by Bryan Organ was commissioned by private subscription to become part of the collection of the Royal Society. Accepted by the president of the society on 25 March 1982, it was the first portrait of a woman Fellow to be included in the Society's collection.
== Membership of scientific organizations == Hungarian Chemical Society Hungarian Biochemical Society Committee of Peptide Research of Hungarian Academy of Sciences Society of Hungarian Oncologists Member of the Council of Res.Institutes of Hungarian Academy of Sciences European Peptide Society American Peptide Society International Society of Oncodevelopmental Biology and Medicine European Association for Cancer Research Executive Committee of EC European Biotechnology Consortium President of the Curatorium of the Szekerke Mária Cancer Research Foundation Vice President of the European Biotechnology Thematic Network Association (2009–2011) Member of the Healthcare Council of EuropaBio
Sources: en.wikipedia.org
=== CD200 === Basophil function is inhibited by CD200. Herpesvirus-6, herpesvirus-7, and herpesvirus-8 produce a CD200 homolog which also inhibits basophil function. This suggests that basophils may play a role in the immune response to these viruses. The role of basophils in the immune response to these viruses is further supported by findings that the CD200 receptor is expressed more frequently in basophils than in other circulating leukocytes.
=== Mass-balance equations === In general, the calculations are rather complicated or complex. For instance, in the case of a dibasic acid, H2A dissolved in water the two reactants can be specified as the conjugate base, A2−, and the proton, H+. The following equations of mass-balance could apply equally well to a base such as 1,2-diaminoethane, in which case the base itself is designated as the reactant A:
10 June The VC announced that it had selected leaders for its "Provisional Revolutionary Government of the Republic of South Vietnam" (PRG), a "government in exile" to assume leadership if the VC and North Vietnam were successful in conquering South Vietnam. Former South Vietnamese lawyer and VC president Nguyễn Hữu Thọ was named as chairman of the advisory council to the PRG, and Huỳnh Tấn Phát was named the PRG Council President.
== Composition == OFM comprises more than 24 collagens (most notably types I and III), but also contains many growth factors, polysaccharides and proteoglycans that naturally exist as part of the extracellular matrix and play important roles in wound healing and soft tissue repair. The composition includes more than 150 different proteins, including elastin, fibronectin, glycosaminoglycans, basement membrane components, and various growth factors, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet derived growth factor (PDGF). OFM has been shown to recruit mesenchymal stem cells, stimulate cell proliferation, angiogenesis and vascularogenesis, and modulate matrix metalloproteinase and neutrophil elastase. The porous structure of OFM has been characterized by differential scanning calorimetry (DSC), scanning electron microscopy (SEM), atomic force microscopy (AFM), histology, Sirius Red staining, small-angle x-ray scattering (SAXS), and micro computerized topography (MicroCT). OFM has been shown to contain residual vascular channels that facilitate blood vessel formation through angioconduction.
=== Pests === Common herbarium pests include: silverfish, book lice (psocids), cigarette or tobacco beetles (Lasioderma), dermestids, drugstore beetles (Stegobium paniceum) A reoccurring threat to the longevity of herbarium specimens is insects, a number of which find dried plants palatable. Historically, various methods have been used to kill insects, which either come in with the plants when they are collected or are in the building where the plants are stored. Pests are commonly treated with two different methods:
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.